Skip to main content

Soluble P-selectin and correlation with Prothrombin Fragment 1 + 2 in myeloid malignancies in Cipto Mangunkusumo general hospital



Myeloid cells express microparticles that could increase the expression of adhesion molecules including P-selectin. We aimed to evaluate the level of soluble P-selectin (sP-selectin) and prothrombin fragment 1 + 2 (F1 + 2), and to determine correlation of sP-selectin with leukocyte count and F1 + 2 levels in acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) patients.


Patients with newly diagnosed AML (n = 25), CML (n = 13), and controls (n = 17) were recruited in this study. The diagnosis of AML and CML is based on 2001 WHO and/or FAB criteria. Levels of sP-selectin and F1 + 2 were determined using enzyme-linked immunosorbent assay kits (Behring ELISA Processor-III® and Behring Enzygnost F1 + 2).


sP-selectin was significantly elevated in CML patients compared to AML patients (p = 0.001). Levels of F1 + 2 in AML and CML patients were significantly increased in comparison to controls (p < 0.001 and p = 0.043). Levels of sP-selectin were significantly correlated to leukocyte count (r = 0.437; p = 0.029) and F1 + 2 (r = 0.436; p = 0.029) in AML patients.


AML and CML patients had an increased tendency to thrombosis. While CML patients had higher platelet and/or endothelial activation, hypercoagulable state are more pronounced in AML patients.


Malignancies are associated with the development of thromboembolic event, approximately up to six-fold higher than the general population. The pathogenesis of cancer-associated thrombosis (CAT) is multifactorial and complex, mainly related to components of Virchow’s triad [1, 2]. Cancer cells may alter hemostasis by secreting procoagulant factors and interacting with endothelial cells to trigger a coagulation cascade [3].

Patients with hematological malignancy also carry an increased risk of cancer-associated thrombosis. A recent meta-analysis reported that venous thromboembolism (VTE) events were highest in CML patients among other leukemia subtypes [4]. Circulating microparticles and adhesion molecules play an important role in the mechanism of thrombus formation in hematologic malignancies [5].

P-selectin is expressed on activated platelets and endothelium. Interaction with its ligand, P-selectin glycoprotein ligand 1 (PSGL-1), on leukocytes mediates adherence of leukocytes to endothelium and activated platelets and shedding of P-selectin into the circulation as soluble P-selectin (sP-selectin). Soluble P-selectin, in dimeric or multimeric form, may play a role in thrombogenesis by forming a stable leukocyte-platelet aggregates [6,7,8].

Prothrombin fragment 1 + 2, thrombin-antithrombin complex (TAT), and soluble fibrin have been reported to reflect thrombin formation in early phase of thrombosis, whereas D-dimer reflects fibrin degradation products in secondary fibrinolysis [9,10,11]. Ota et al. found that levels of F1 + 2 in plasma were significantly correlated to TAT, soluble fibrin, and D-dimer. They found that with a cutoff value of F1 + 2 for diagnosis of thrombosis of 300 pmol/L, the sensitivity and specificity were 86.2 and 80.6% respectively [9]. Thus, F1 + 2 is considered as a useful parameter for a hypercoagulable state and for the diagnosis of all types of thrombosis.

The aim of this study was to investigate levels of sP-selectin in myeloid malignancies (AML and CML) patients, and to evaluate its correlation with activation coagulation (F1 + 2) and leukocyte count that specific for hematologic malignancy.

Subjects and method

This was a cross-sectional study conducted at Hematology - Medical Oncology Division in Cipto Mangunkusumo General Hospital, Jakarta, Indonesia, from January to June 2012. Subjects were newly diagnosed AML and CML based on WHO and/or French-American British (FAB) criteria, aged 18 years or older. We also collected samples from healthy individuals (controls) who were free of any diseases, as confirmed by annual medical checkup, and did not take any anticoagulant and/or antiplatelet medication. Patients were excluded from the study in case of pregnancy, severe infection, immobilization for at least 3 days, during intensive chemotherapy, or refused to participate in the study. The study protocol was approved by the local Ethics Committee from Faculty of Medicine, Universitas Indonesia. All subjects signed the informed consent forms before the study.

Venous blood sample was drawn from each subject before starting chemotherapy and divided into an EDTA vacutainer for complete blood count and sP-selectin measurements, and into a 3.8% sodium citrate (9 parts of whole blood and 1 part of sodium citrate at 0.129 mmol/L) vacutainer for the determination of F1 + 2. Platelet-poor plasma was obtained by blood centrifugation, then aliquoted and stored at − 20 °C until testing.

Hemoglobin (Hb), platelet counts, and leukocyte counts were determined using an automated blood analyzer (ABX Micros 60® analyzer). Commercial enzyme-linked immunosorbent assay/ELISA kits were used to measure plasma levels sP-selectin (Behring ELISA Processor-III®, Dade Behring) and F1 + 2 (Enzygnost F1 + 2, Dade Behring) according to manufacturer’s instructions.

Statistical analysis

The data were not normally distributed, hence expressed as median and interquartile range (IQR). Statistical significance between two groups were determined using Mann-Whitney U test for nonparametric variables. The correlation between two variables was evaluated by Spearman’s correlation analysis. A p-value < 0.05 indicates statistically significant difference. All statistical analysis was performed with SPSS version 24 for Mac.


A total of 55 subjects were enrolled in the study. The study population comprised of 17 healthy subjects (controls), 25 AML patients, and 13 CML patients. In control group, the median age was 40 years (IQR 22 years) and 70.59% of subjects were males. In AML group, the median age at diagnosis was 32 years (IQR 17 years) and 60% of subjects were males. In CML group, the median age at diagnosis was 47 years (IQR 32 years) and 53.85% of subjects were males. Hematological characteristics of the subjects are shown in Table 1. AML and CML groups had lower hemoglobin (Hb) and marked increased of leukocyte and blast count as compared to controls. Platelet count was markedly reduced in AML group.

Table 1 Characteristics of the subjects

As shown in Table 2 and Fig. 1, AML patients had increased levels of sP-selectin and F1 + 2 compared to controls, but only F1 + 2 reaching statistically significant (median 519.03 pmol/L; p < 0.001 vs. controls). CML patients had significantly increased levels of both sP-selectin (median 0.25 ng/mL) and F1 + 2 (median 370.16 pmol/L) compared to controls (p < 0.001 and p = 0.043 respectively). While sP-selectin levels were significantly higher in CML than in AML patients (median 0.25 ng/mL vs. 0.14 ng/mL, p = 0.001), F1 + 2 levels were higher in AML than in CML patients, despite being not statistically significant.

Table 2 Plasma levels of sP-selectin and F1 + 2
Fig. 1
figure 1

Plasma levels of sP-selectin and F1 + 2. The box shows 25th percentile, median, and 75th percentile. A p-value < 0.05 indicates statistically significance

The correlation analysis according to disease type showed that sP-selectin was significantly correlated to either leukocyte count (r = 0.437; p = 0.029) and F1 + 2 (r = 0.436; p = 0.029) in AML patients only. There was no significant correlation among leukocyte count, sP-selectin, and F1 + 2 in controls and CML patients (Table 3).

Table 3 sP-selectin correlation with Leukocyte count and F1 + 2


This present study investigated the plasma levels of sP-selectin, a marker of platelet and endothelial activation, and F1 + 2, a marker of early phase of thrombosis, in 17 controls and 38 patients with AML and CML.

P-selectin is an adhesion molecule stored in Weibel-Palade bodies of endothelial cells and alpha-granules of platelets. It is the largest of the known selectins, along with E-selectin (expressed by endothelial cells) and L-selectin (expressed by leukocytes) [8, 12]. Several studies reported that acute leukemia are related to higher platelet activation. Mechanisms leading such activation are: (1) leukemic cells cause endothelial cells damage while invading bone marrow, body tissues, and organs; (2) leukemic cells release procoagulant molecules; (3) leukemic cells express adhesion molecules; (4) chemotherapeutic agents cause endothelium damage; (5) leukemic cells release higher levels of cytokine and chemokines [13]. Cytokines released by blast cells can induce the expression of P-selectin [8].

Upon activation, P-selectin is mobilized to the external membrane to mediate leukocyte adherence [8, 12]. Role of P-selectin in coagulation cascade can be explained by two ways. First, P-selectin may support platelet-platelet interaction. Secondly, P-selectin on platelet surface promotes leukocyte recruitment and facilitates binding of tissue factor-bearing microparticles (TF-MP), derived from normal cells or cancer cells, to leukocytes via PSGL-1 [8, 14, 15]. Additionally, adhesion of leukocytes to P-selectin via PSGL-1 induces shedding of P-selectin into the circulation. Increased concentrations of soluble form of P-selectin (sP-selectin) from activated platelets or activated endothelial cells are associated with VTE events in cancer patients [16, 17]. A possible mechanism is that sP-selectin can activate leukocytes via PSGL-1 to generate TF-MP which contribute to pro-coagulant state [11, 18].

In the present study, plasma levels of sP-selectin were increased significantly in CML patients in relation to AML patients and controls. This findings were supported by Cella et al. who demonstrate a significant increased levels of sP-selectin in myeloproliferative neoplasms (MPN) patients compared to controls [12]. Furthermore, this might be related to higher platelet counts in CML patients than in AML patients, as seen in our patients (median 417 × 103/mm3 vs. 67 × 103/mm3, p < 0.05). Leinoe et al. clarified that low P-selectin expression on stimulated AML platelets are due to reduced platelet synthesis as well as alpha-granules dysfunction [19]. Platelet abnormalities and/or dysfunction have also been reported in CML patients. However, this may be of particular importance in AML patients as AML is a rapidly progressive disease with severe quantitative platelet defect [20, 21].

In our study, both AML and CML patients had increased concentrations of F1 + 2 in relation to controls (p < 0.05). These results are similar to a study by Negaard et al. They found that the baseline values (before cancer therapy) of F1 + 2 were increased among of patients with hematological malignancies, including AML, compared to controls. Levels of F1 + 2 in plasma decreased significantly after cancer treatment (median 281.8 pM vs. 258.6 pM, p = 0.03), but remained significantly higher than controls (median 258.6 pM vs. 1.3 pM, p < 0.001) [22]. Thus, the state of hypercoagulability in myeloid malignancy is high at baseline and even after termination of cancer treatment. Moreover, the higher levels of F1 + 2 in AML than CML and controls are related to higher expression of tissue factors in AML [23, 24].

Moreover, sP-selectin was positively correlated to leukocyte count and F1 + 2 (p = 0.029 for both) only in AML patients, reflecting the interplay between platelet and/or endothelial activation and inflammation. This agrees with Wakefield and Myers who demonstrated that thrombosis and inflammation are inter-related [25]. Indeed, high leukocyte count in leukemia are associated with higher incidence of vascular complications. One potential mechanism to support this concept is that leukemic cells are able to activate endothelial cells via various cytokines, such as tumor necrosis factor alpha (TNF-α). Subsequent attachment of leukemic cells to the vessel wall via adhesion molecules induces coagulation activation and leukocyte aggregation [26]. This may explain the correlation between leukocyte count and sP-selectin as well as sP-selectin and F1 + 2 in AML patients of our study. Differently, in CML patients, plasma sP-selectin levels were not correlated with leukocyte count and F1 + 2. It might be possible that we could not detect direct correlation between those biomarkers because of the small group of CML patients.

On the other hand, PSGL-1 is predominantly expressed on myeloblast (AML blasts) rather than lymphoblast to interact with either P- or E-selectins. It is not only able to induce coagulation activation, but also promoting blast cells survival, drug resistance, and metastasis [8, 27]. Thus, inhibiting selectins interaction with their ligands may provide a new promising thromboprophylaxis, especially in AML in patients who carry high risk of bleeding during anticoagulant due to severe thrombocytopenia.

Some limitations of this study need to be acknowledged: (1) significant results may be hampered by a relatively small sample size; (2) we did not consider other congenital or acquired thrombophilia that might contribute to thrombotic risk. However, the results of this study may serve as a basis for future observational or interventional studies on thromboprophylaxis in hematological malignancies.


In conclusion, this study provides direct evidence that AML and CML patients had an increased tendency to thrombosis. While CML patients had higher platelet and/or endothelial activation, hypercoagulable state are more pronounced in AML patients.

Availability of data and materials

The datasets used in the current study are available from the corresponding author on reasonable request.



Acute myeloid leukemia


Cancer-associated thrombosis


Chronic myeloid leukemia


Enzyme-linked immunosorbent assay

F1 + 2:

Prothrombin fragment 1 + 2


French-American British




Interquartile range


P-selectin glycoprotein ligand 1


soluble P-selectin


Thrombin-antithrombin complex


Tissue factor-bearing microparticles


Tumor necrosis factor


Venous thromboembolism


  1. Visweshwar N, Jaglal M, Sokol L, Djulbegovic B. Hematological malignancies and arterial thromboembolism. Indian J Hematol Blood Transfus. 2019;35(4):611–24.

    Article  Google Scholar 

  2. Khorana AA, Dalal M, Lin J, Connolly GC. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States: VTE in ambulatory US cancer patients. Cancer. 2013;119(3):648–55.

    Article  CAS  Google Scholar 

  3. Hanna DL, White RH, Wun T. Biomolecular markers of cancer-associated thromboembolism. Crit Rev Oncol Hematol. 2013;88(1):19–29.

    Article  Google Scholar 

  4. Wu Y-Y, Tang L, Wang M-H. Leukemia and risk of venous thromboembolism: a meta-analysis and systematic review of 144 studies comprising 162,126 patients. Sci Rep. 2017;7(1):1167.

    Article  Google Scholar 

  5. Elmoamly S, Afif A. Can biomarkers of coagulation, platelet activation, and inflammation predict mortality in patients with hematological malignancies? Hematology. 2018;23(2):89–95.

    Article  CAS  Google Scholar 

  6. McEver RP. Selectins: initiators of leucocyte adhesion and signalling at the vascular wall. Cardiovasc Res. 2015;107(3):331–9.

    Article  CAS  Google Scholar 

  7. Kappelmayer J, Nagy B. The interaction of selectins and PSGL-1 as a key component in thrombus formation and cancer progression. Biomed Res Int. 2017;2017:1–18.

    Article  Google Scholar 

  8. Spertini C, Baïsse B, Bellone M, Gikic M, Smirnova T, Spertini O. Acute myeloid and lymphoblastic leukemia cell interactions with endothelial selectins: critical role of PSGL-1, CD44 and CD43. Cancers. 2019;11(9):1253.

    Article  CAS  Google Scholar 

  9. Ota S, Wada H, Abe Y, Yamada E, Sakaguchi A, Nishioka J, et al. Elevated levels of prothrombin fragment 1 + 2 indicate high risk of thrombosis. Clin Appl Thromb Hemost. 2008;14(3):279–85.

    Article  CAS  Google Scholar 

  10. Wada H, Kobayashi T, Abe Y, Hatada T, Yamada N, Sudo A, et al. Elevated levels of soluble fibrin or D-dimer indicate high risk of thrombosis. J Thromb Haemost. 2006;4(6):1253–8.

    Article  CAS  Google Scholar 

  11. Pabinger I, Thaler J, Ay C. Biomarkers for prediction of venous thromboembolism in cancer. Blood. 2013;122(12):2011–8.

    Article  CAS  Google Scholar 

  12. Cella G, Marchetti M, Vianello F, Panova-Noeva M, Vignoli A, Russo L, et al. Nitric oxide derivatives and soluble plasma selectins in patients with myeloproliferative neoplasms. Thromb Haemost. 2010;104(07):151–6.

    Article  CAS  Google Scholar 

  13. Qian X, Wen-jun L. Platelet changes in acute leukemia. Cell Biochem Biophys. 2013;67(3):1473–9.

    Article  CAS  Google Scholar 

  14. Nomura S, Niki M, Nisizawa T, Tamaki T, Shimizu M. Microparticles as biomarkers of blood coagulation in cancer. Biomark Cancer. 2015;7:51–6.

    Article  CAS  Google Scholar 

  15. André P. P-selectin in haemostasis. Br J Haematol. 2004;126(3):298–306.

    Article  Google Scholar 

  16. Ay C, Jungbauer LV, Sailer T, Tengler T, Koder S, Kaider A, et al. High concentrations of soluble P-selectin are associated with risk of venous thromboembolism and the P-selectin Thr715 variant. Clin Chem. 2007;53(7):1235–43.

    Article  CAS  Google Scholar 

  17. Ay C, Simanek R, Vormittag R, Dunkler D, Alguel G, Koder S, et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and thrombosis study (CATS). Blood. 2008;112(7):2703–8.

    Article  CAS  Google Scholar 

  18. André P, Hartwell D, Hrachovinová I, Saffaripour S, Wagner DD. Pro-coagulant state resulting from high levels of soluble P-selectin in blood. Proc Natl Acad Sci U S A. 2000;97(25):13835–40.

    Article  Google Scholar 

  19. Leinoe EB, Hoffmann MH, Kjaersgaard E, Nielsen JD, Bergmann OJ, Klausen TW, et al. Prediction of haemorrhage in the early stage of acute myeloid leukaemia by flow cytometric analysis of platelet function. Br J Haematol. 2005;128(4):526–32.

    Article  Google Scholar 

  20. Villmow T, Kemkes-Matthes B, Matzdorff AC. Markers of platelet activation and platelet–leukocyte interaction in patients with myeloproliferative syndromes. Thromb Res. 2002;108(2–3):139–45.

    Article  CAS  Google Scholar 

  21. Foss B, Bruserud Ø. Platelet functions and clinical effects in acute myelogenous leukemia. Thromb Haemost. 2008;99(01):27–37.

    Article  CAS  Google Scholar 

  22. Negaard H, Iversen P, Østenstad B, Iversen N, Holme P, Sandset P. Hypercoagulability in patients with haematological neoplasia: no apparent initiation by tissue factor. Thromb Haemost. 2008;99(06):1040–8.

    Article  CAS  Google Scholar 

  23. Dicke C, Amirkhosravi A, Spath B, Jiménez-Alcázar M, Fuchs T, Davila M, et al. Tissue factor-dependent and -independent pathways of systemic coagulation activation in acute myeloid leukemia: a single-center cohort study. Exp Hematol Oncol. 2015;4(1):22.

    Article  Google Scholar 

  24. Ribatti D. Tissue factor in hematological malignancies. Leukemia. 2006;20(8):1356–7.

    Article  CAS  Google Scholar 

  25. Wakefield TW, Myers DD. Venous thromboembolism – the intersection of thrombosis and inflammation. Eur Oncol Haematol. 2007;1(1):52–4.

    Article  Google Scholar 

  26. Falanga A, Russo L, Tartari CJ. Pathogenesis and treatment of thrombohemorrhagic diathesis in acute promyelocytic leukemia. Mediterr J Hematol Infect Dis. 2011;3(1):e2011068.

    Article  Google Scholar 

  27. Guan X. Cancer metastases: challenges and opportunities. Acta Pharm Sin B. 2015;5(5):402–18.

    Article  Google Scholar 

Download references


The author would like to thank our scientists, Elly Yanah Arwanih, M.Biomed who helped the sP-selectin examination and Puspita who helped with the F1 + 2 examination.


No funding was received for this study.

Author information

Authors and Affiliations



The corresponding author takes 100% responsibility for the paper as a whole. The author read and approved the final manuscript.

Corresponding author

Correspondence to Lugyanti Sukrisman.

Ethics declarations

Ethics approval and consent to participate

The study was approved by the Local Ethics Committee at Faculty of Medicine, Universitas Indonesia (approval no. 316/PT02.FK/ETIK/2007). Written informed consent was obtained from all participants in accordance with Declaration of Helsinki.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sukrisman, L. Soluble P-selectin and correlation with Prothrombin Fragment 1 + 2 in myeloid malignancies in Cipto Mangunkusumo general hospital. Thrombosis J 19, 51 (2021).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI:


  • sP-selectin
  • F1 + 2
  • AML
  • CML